Evidence map›Paper›PMID 34884541›Full record

ArticleInternational journal of molecular sciences2021

CCL4 Stimulates Cell Migration in Human Osteosarcoma via the mir-3927-3p/Integrin αvβ3 Axis.

Hsiao-Chi Tsai, Yan-You Lai, Hsuan-Chih Hsu, Yi-Chin Fong, Ming-Yu Lien, Chih-Hsin Tang

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. TheCancers · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Hsiao-Chi TsaiSchool of Medicine, China Medical University, Taichung 404022, Taiwan.
Yan-You LaiSchool of Chinese Medicine, China Medical University, Taichung 406040, Taiwan.
Hsuan-Chih HsuDepartment of Medical Research, Chung Shan Medical University, Taichung 40201, Taiwan.
Yi-Chin FongDepartment of Sports Medicine, College of Health Care, China Medical University, Taichung 404022, Taiwan.
Ming-Yu LienSchool of Medicine, China Medical University, Taichung 404022, Taiwan.
Chih-Hsin TangSchool of Medicine, China Medical University, Taichung 404022, Taiwan.ORCID 0000-0002-7113-8352
China Medical University · TWAsia University · TWChung Shan Medical University · TW

Funding

China Medical University Hospital DMR-110-017Taiwan's Ministry of Science and Technology MOST 108-2314-B-039-034-MY3
6 · The paper itself

Abstract

Osteosarcoma is the most common type of primary malignant bone cancer, and it is associated with high rates of pulmonary metastasis. Integrin αvβ3 is critical for osteosarcoma cell migratory and invasive abilities. Chemokine (C-C motif) ligand 4 (CCL4) has diverse effects on different cancer cells through its interaction with its specific receptor, C-C chemokine receptor type 5 (CCR5). Analysis of mRNA expression in human osteosarcoma tissue identified upregulated levels of CCL4, integrin αv and β3 expression. Similarly, an analysis of records from the Gene Expression Omnibus (GEO) dataset showed that CCL4 was upregulated in human osteosarcoma tissue. Importantly, the expression of both CCL4 and integrin αvβ3 correlated positively with osteosarcoma clinical stages and lung metastasis. Analysis of osteosarcoma cell lines identified that CCL4 promotes integrin αvβ3 expression and cell migration by activating the focal adhesion kinase (FAK), protein kinase B (AKT), and hypoxia inducible factor 1 subunit alpha (HIF-1α) signaling pathways, which can downregulate microRNA-3927-3p expression. Pharmacological inhibition of CCR5 by maraviroc (MVC) prevented increases in integrin αvβ3 expression and cell migration. This study is the first to implicate CCL4 as a potential target in the treatment of metastatic osteosarcoma.

Indexed as

Cell MovementGene Expression Regulation, NeoplasticApoptosisBiomarkers, TumorBone NeoplasmsCell ProliferationChemokine CCL4HumansIntegrin alphaVbeta3MicroRNAsOsteosarcomaTumor Cells, CulturedBiomarkers, TumorCCL4 protein, humanChemokine CCL4Integrin alphaVbeta3MicroRNAsCCL4integrinmetastasismiR-3927-3posteosarcoma

Identifiers

PMID34884541
PMCPMC8657600
OpenAlexW3216164692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.